At a glance
ClinicalIndex Comparison Record- ✓Age 18-45 years
- ✓BMI 18 to <25 kg/m2
- ✕Current prescription medications (except hormonal birth control)
- ✕Amino acid supplements or supplemental protein; unwilling to discontinue 1 week prior
- ✕Tobacco use in past 30 days
- ✕Prior or current cardiovascular, renal, or liver disease
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of Acute Lysine Administration on α-aminoadipic Acid
In Brief
A Phase 1 clinical trial evaluating C-13 labeled Lysine and Normal saline for Healthy. Completed, enrolled 2 participants across 1 site.
Detailed Summary
This sub-study aims to assess the effect and breakdown of lysine administration, specifically examining whether it leads to increased plasma 2-AAA in healthy humans.
Study Details
Timeline
Interventions
Carbon-13 is a stable naturally occurring heavy isotope of carbon. Inclusion of a 13C label on lysine allows for subsequent differentiation between endogenous and exogenous lysine and 2-AAA for calculation of clearance and excretion of the lysine bolus.
Because patients will have multiple blood draws during the course of the study, subjects will have an IV placed to reduce the number of needle sticks. To keep the vein open for blood collections, we will infuse Normal (0.9%) Saline (NS) at a rate of approximately 10ml/hr in order to keep the line open.